Immunocore Holdings PLC
IMCR31.980USD
+1.060+3.43%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
1.59BValor de mercado
PerdaP/L TTM
Mais detalhes de Immunocore Holdings PLC Empresa
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Informações de Immunocore Holdings PLC
Código da empresaIMCR
Nome da EmpresaImmunocore Holdings PLC
Data de listagemFeb 05, 2021
CEOJallal (Bahija)
Número de funcionários493
Tipo de títulosDepository Receipt
Fim do ano fiscalFeb 05
Endereço92 Park Drive Milton Park
CidadeABINGDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalOX14 4RY
Telefone441235438600
Sitehttps://www.immunocore.com/
Código da empresaIMCR
Data de listagemFeb 05, 2021
CEOJallal (Bahija)
Executivos da empresa Immunocore Holdings PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 24 de jan
Atualizado em: sáb, 24 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
14.19%
RTW Investments L.P.
9.78%
Wellington Management Company, LLP
9.60%
Fidelity Management & Research Company LLC
8.81%
PRIMECAP Management Company
7.54%
Outro
50.08%
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
14.19%
RTW Investments L.P.
9.78%
Wellington Management Company, LLP
9.60%
Fidelity Management & Research Company LLC
8.81%
PRIMECAP Management Company
7.54%
Outro
50.08%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.78%
Hedge Fund
28.59%
Investment Advisor/Hedge Fund
24.70%
Venture Capital
1.71%
Research Firm
1.62%
Private Equity
0.77%
Pension Fund
0.57%
Family Office
0.05%
Individual Investor
0.03%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
302
50.63M
101.68%
-9.63M
2025Q3
300
49.40M
99.22%
-6.80M
2025Q2
293
49.19M
99.31%
-10.02M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Investment Management, Inc.
7.06M
14.19%
-3.76K
-0.05%
Sep 30, 2025
RTW Investments L.P.
4.87M
9.78%
--
--
Sep 30, 2025
Wellington Management Company, LLP
4.78M
9.6%
-352.01K
-6.86%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.39M
8.81%
-432.38K
-8.97%
Sep 30, 2025
PRIMECAP Management Company
3.75M
7.54%
-16.91K
-0.45%
Sep 30, 2025
Bellevue Asset Management AG
2.80M
5.62%
--
--
Sep 30, 2025
Tang Capital Management, LLC
2.61M
5.23%
+300.00K
+13.01%
Oct 17, 2025
Baker Bros. Advisors LP
2.32M
4.66%
--
--
Sep 30, 2025
Deep Track Capital LP
1.80M
3.61%
--
--
Sep 30, 2025
BVF Partners L.P.
1.57M
3.16%
+550.00K
+53.70%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Virtus LifeSci Biotech Products ETF
1.49%
Tema Oncology ETF
1.11%
ALPS Medical Breakthroughs ETF
0.7%
ProShares Ultra Nasdaq Biotechnology
0.19%
SPDR S&P International Small Cap ETF
0.17%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Intl Small Cap Equity Factor ETF
0.12%
iShares Biotechnology ETF
0.1%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Ver Mais
Virtus LifeSci Biotech Products ETF
Proporção1.49%
Tema Oncology ETF
Proporção1.11%
ALPS Medical Breakthroughs ETF
Proporção0.7%
ProShares Ultra Nasdaq Biotechnology
Proporção0.19%
SPDR S&P International Small Cap ETF
Proporção0.17%
Invesco Nasdaq Biotechnology ETF
Proporção0.13%
iShares Intl Small Cap Equity Factor ETF
Proporção0.12%
iShares Biotechnology ETF
Proporção0.1%
SPDR Portfolio Developed World ex-US ETF
Proporção0.01%
Fidelity Nasdaq Composite Index ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
